



President: Prof. A. Verstraete

Final program

BLT Scientific Session and General Assembly - online meeting

22nd of March 2021 15:00 (GMT+1)

15:00-15:10 **Welcome by our president**

15:10-15:50 **Surveillance strategies for tracking emerging drug trends in the United States in the absence of a National Early Warning System**

Barry Logan, MD PhD

16:00-17:20 **Free communications**

- Paraparesis and thromboembolic disease caused by abuse of nitrous oxide and alcohol: A case report
B. Declerck, A. Mortier, B. Blomme, I. Weets, K. Lanckmans
- A screening method for NPS using the HighresNPS and Mzcloud collaborative platforms
A. Verstraete, N. Verougstraete, E. Hyde
- Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS/MS method
N. Verougstraete, V. Stove, A. Verstraete, C. Stove
- Fully Automated Dried Blood Spot-Based Therapeutic Drug Monitoring of Immunosuppressants
S. Deprez and C. Stove
- Synthesis, Functional evaluation and molecular docking of NBOME and NBF positional isomers
E. Pottie, O. Kupriyanova, A. Brandt, R. Laprairie, V. Shevyrin and C. Stove
- Sensing HIF activation: promising activity-based bioassays to screen for performance enhancing HIF stabilizers
L. Janssens, C. Stove
- Synthesis, chemical characterization, and μ -opioid receptor activity assessment of the emerging group of 'nitazene' 2-benzylbenzimidazole synthetic opioids
M. Vandeputte, K. Van Uytfanghe, N. Layle, D. St. Germaine, D. Iula, C. Stove
- Designer benzodiazepines in Belgium: a snapshot through retrospective analysis
M. Degreef, E. Berry, A. Verstraete, K. Maudens, A. van Nuijs

17:20-17:30 **General Assembly**

- Updates
- Financial statements